96 related articles for article (PubMed ID: 26731899)
1. [Alternative Splicing Detection as a Biomarker for Cancer Diagnosis: A Novel Progressive Mechanism of Acute Lymphoblastic Leukemia with Alternative Splicing as a Biomarker Candidate].
Kitamura K; Matsushita K; Kobayashi S; Ishige T; Semba T; Kimura A; Kazami T; Ohyama M; Itoga S; Beppu M; Nishimura M; Satoh M; Nomura F
Rinsho Byori; 2015 Sep; 63(9):1091-102. PubMed ID: 26731899
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
[TBL] [Abstract][Full Text] [Related]
3. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.
Matsushita K; Kajiwara T; Tamura M; Satoh M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Yoshimoto R; Ito A; Kubo S; Natsume T; Levens D; Yoshida M; Nomura F
Mol Cancer Res; 2012 Jun; 10(6):787-99. PubMed ID: 22496461
[TBL] [Abstract][Full Text] [Related]
4. [Alternative Splicing Detection as Biomarker Candidates for Cancer Diagnosis and Treatment with Establishment of Clinical Biobank in Chiba University].
Matsushita K; Itoga S; Nishimura M; Furuta K; Nomura F
Rinsho Byori; 2015 Mar; 63(3):347-60. PubMed ID: 26524858
[TBL] [Abstract][Full Text] [Related]
5. SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues.
Kajiwara T; Matsushita K; Itoga S; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Habara Y; Matsuo M; Nomura F
Cancer Sci; 2013 Feb; 104(2):149-56. PubMed ID: 23113893
[TBL] [Abstract][Full Text] [Related]
6. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.
Rahmutulla B; Matsushita K; Satoh M; Seimiya M; Tsuchida S; Kubo S; Shimada H; Ohtsuka M; Miyazaki M; Nomura F
Oncotarget; 2014 May; 5(9):2404-17. PubMed ID: 24811221
[TBL] [Abstract][Full Text] [Related]
8. Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.
Ogura Y; Hoshino T; Tanaka N; Ailiken G; Kobayashi S; Kitamura K; Rahmutulla B; Kano M; Murakami K; Akutsu Y; Nomura F; Itoga S; Matsubara H; Matsushita K
Oncotarget; 2018 May; 9(33):22929-22944. PubMed ID: 29796163
[TBL] [Abstract][Full Text] [Related]
9. Post-transcriptional regulation of BRG1 by FIRΔexon2 in gastric cancer.
Ailiken G; Kitamura K; Hoshino T; Satoh M; Tanaka N; Minamoto T; Rahmutulla B; Kobayashi S; Kano M; Tanaka T; Kaneda A; Nomura F; Matsubara H; Matsushita K
Oncogenesis; 2020 Feb; 9(2):26. PubMed ID: 32071290
[TBL] [Abstract][Full Text] [Related]
10. The Link of mRNA and rRNA Transcription by PUF60/FIR through TFIIH/P62 as a Novel Therapeutic Target for Cancer.
Kitamura K; Hoshino T; Okabe A; Fukuyo M; Rahmutulla B; Tanaka N; Kobayashi S; Tanaka T; Shida T; Ueda M; Minamoto T; Matsubara H; Kaneda A; Ishii H; Matsushita K
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139171
[TBL] [Abstract][Full Text] [Related]
11. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
[TBL] [Abstract][Full Text] [Related]
12.
Kimura A; Kitamura K; Ailiken G; Satoh M; Minamoto T; Tanaka N; Nomura F; Matsushita K
Oncotarget; 2017 Sep; 8(40):67955-67965. PubMed ID: 28978087
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
[TBL] [Abstract][Full Text] [Related]
14. Anti-FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.
Kobayashi S; Hiwasa T; Ishige T; Rahmutulla B; Kano M; Hoshino T; Minamoto T; Shimada H; Nomura F; Matsubara H; Matsushita K
Cancer Sci; 2019 Jun; 110(6):2004-2013. PubMed ID: 30980774
[TBL] [Abstract][Full Text] [Related]
15. Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.
Kobayashi S; Hoshino T; Hiwasa T; Satoh M; Rahmutulla B; Tsuchida S; Komukai Y; Tanaka T; Matsubara H; Shimada H; Nomura F; Matsushita K
Oncotarget; 2016 Dec; 7(50):82493-82503. PubMed ID: 27756887
[TBL] [Abstract][Full Text] [Related]
16. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis.
Matsushita K; Tomonaga T; Shimada H; Shioya A; Higashi M; Matsubara H; Harigaya K; Nomura F; Libutti D; Levens D; Ochiai T
Cancer Res; 2006 Feb; 66(3):1409-17. PubMed ID: 16452196
[TBL] [Abstract][Full Text] [Related]
17. [Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment].
Matsushita K; Kajiwara T; Itoga S; Satoh M; Sogawa K; Umemura H; Sawai S; Nishimura M; Tamura M; Tanaka N; Shimada H; Tomonaga T; Nomura F
Rinsho Byori; 2009 Dec; 57(12):1151-8. PubMed ID: 20077813
[TBL] [Abstract][Full Text] [Related]
18. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.
Hahn CN; Venugopal P; Scott HS; Hiwase DK
Immunol Rev; 2015 Jan; 263(1):257-78. PubMed ID: 25510282
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.
Darman RB; Seiler M; Agrawal AA; Lim KH; Peng S; Aird D; Bailey SL; Bhavsar EB; Chan B; Colla S; Corson L; Feala J; Fekkes P; Ichikawa K; Keaney GF; Lee L; Kumar P; Kunii K; MacKenzie C; Matijevic M; Mizui Y; Myint K; Park ES; Puyang X; Selvaraj A; Thomas MP; Tsai J; Wang JY; Warmuth M; Yang H; Zhu P; Garcia-Manero G; Furman RR; Yu L; Smith PG; Buonamici S
Cell Rep; 2015 Nov; 13(5):1033-45. PubMed ID: 26565915
[TBL] [Abstract][Full Text] [Related]
20. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
